Chronic News and Research

RSS

DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that it will present three abstracts at the 3rd North American Chapter meeting of the International Society for Peritoneal Dialysis (ISPD) on August 27-29 in Vancouver, British Columbia.

26 Aug 2009

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

26 Aug 2009

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

26 Aug 2009

Healthy San Francisco enrollees express high levels of satisfaction with city's health access program and survey shows signs of improved access to care

As states and cities struggle with the economic recession and possible fiscal pressure on public health care programs, a new Kaiser Family Foundation survey of enrollees in Healthy San Francisco (HSF), the city's health care access program for the uninsured, reports high rates of satisfaction and signs that the program has improved access to care for those uninsured residents who have enrolled.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Reform efforts focus attention on regional innovations in care delivery

As health reform efforts loom over Congress, news outlets find models of innovation in their own backyards. Geisinger Health System in rural Pennsylvania, a Florida satellite of the Mayo Clinic, Kaiser Permanente Northwest in Oregon and Washington state, and Virginia Commonwealth University Medical Center in Richmond, Va., all get some attention.

26 Aug 2009

Mutations of gene regulators can result in growth disorders

A specific gene is particularly frequently involved in the development of short stature. Researchers in Heidelberg have now discovered that sequences of genetic material on the X and Y chromosome that regulate this gene are also crucial for growth in children.

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Medtronic's Q1 financial results announced

Medtronic, Inc. (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2010, which ended July 31, 2009.

25 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Study reveals safety of ConvaTec's advanced antimicrobial dressing

ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced new data showing that AQUACEL(R) Ag, the company's advanced antimicrobial dressing, is safe for use in an MRI environment.

25 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

LAF report estimates the total economic burden of new cancer cases at $305 billion in 2009

A landmark report released today by the Lance Armstrong Foundation (LAF) estimates the total economic burden of new cancer cases at $305 billion in 2009. The findings are included in the report, "Breakaway: The Global Burden of Cancer - Challenges and Opportunities," released today in Dublin at the premiere LIVESTRONG Global Cancer Summit.

25 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

Report assessing school-based policies that address the health of students released by AAFA

For over 8 million children with asthma, food allergies and related conditions, the school-house is a focal point for managing their diseases. Now for the second year in a row, the Asthma and Allergy Foundation of America (AAFA) has released a report assessing school-based policies that address student health for elementary, middle and high schools in all 50 states.

25 Aug 2009

Chronic News and Research

DaVita to present three abstracts on Peritoneal Dialysis at the ISPD meeting

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Healthy San Francisco enrollees express high levels of satisfaction with city's health access program and survey shows signs of improved access to care

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Reform efforts focus attention on regional innovations in care delivery

Mutations of gene regulators can result in growth disorders

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Medtronic's Q1 financial results announced

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Study reveals safety of ConvaTec's advanced antimicrobial dressing

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

LAF report estimates the total economic burden of new cancer cases at $305 billion in 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

Report assessing school-based policies that address the health of students released by AAFA

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News